Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder

Translational Psychiatry

Volumn 6, Issue 3, 2016, Pages

  Mocking, R J T ^a   Harmsen, I ^a   Assies, J ^a   Koeter, M W J ^a   Ruhe H G ^a,b   Schene, A H ^c,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; ANTIDEPRESSANT AGENT;

ARTICLE; DIET SUPPLEMENTATION; EMBASE; HUMAN; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DIETARY SUPPLEMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS;

EID: 84977128122     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.29     Document Type: Article

References (57)

1. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 2012; 17: 1272–1282.
2. Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D et al. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2006; 84: 1308–1316.
3. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010; 91: 757–770.
4. Appleton KM, Sallis HM, Perry R, Ness AR, Churchill R. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev 2015; 11: CD004692.
5. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 2009; 28: 525–542.
6. Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of Eicosa-pentaenoic Acid (EPA) in clinical trials in depression. J Clin Psychiatry 2011; 72: 1577–1584.
7. Martins JG, Bentsen H, Puri BK. Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive dis-order: a critique of Bloch and Hannestad and updated meta-analysis. Mol Psychiatry 2012; 17: 1144–1149.
8. Lin PY, Mischoulon D, Freeman MP, Matsuoka Y, Hibbeln J, Belmaker RH et al. Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol Psychiatry 2012; 17: 1161–1163; author reply 1163–1167.
9. Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 2014; 9: e96905.
10. Yang JR, Han D, Qiao ZX, Tian X, Qi D, Qiu XH. Combined application of eicosa-pentaenoic acid and docosahexaenoic acid on depression in women: a meta-analysis of double-blind randomized controlled trials. Neuropsychiatr Dis Treat 2015; 11: 2055–2061.
11. Borenstein M. Introduction to Meta-analysis. John Wiley & Sons: Chichester, UK, 2009, xxviii, pp 421.
12. Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008; 42: 192–198.
13. Rizzo AM, Corsetto PA, Montorfano G, Opizzi A, Faliva M, Giacosa A et al. Comparison between the AA/EPA ratio in depressed and non depressed elderly females: omega-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters. Nutr J 2012; 11: 82.
14. Rondanelli M, Giacosa A, Opizzi A, Pelucchi C, La Vecchia C, Montorfano G et al. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr 2010; 29: 55–64.
15. Rondanelli M, Giacosa A, Opizzi A, Pelucchi C, La Vecchia C, Montorfano G et al. Long chain omega 3 polyunsaturated fatty acids supplementation in the treatment of elderly depression: effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life. J Nutr Health Aging 2011; 15: 37–44.
16. Lesperance F, Frasure-Smith N, St-Andre E, Turecki G, Lesperance P, Wisniewski SR. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry 2011; 72: 1054–1062.
17. Mozaffari-Khosravi H, Yassini-Ardakani M, Karamati M, Shariati-Bafghi SE. Eicosa-pentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2013; 23: 636–644.
18. Lucas M, Asselin G, Merette C, Poulin MJ, Dodin S. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr 2009; 89: 641–651.
19. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59: 913–919.
20. da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 2008; 111: 351–359.
21. Assies J, Mocking RJ, Lok A, Ruhe HG, Pouwer F, Schene AH. Effects of oxidative stress on fatty acid-and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr Scand 2014; 130: 163–180.
22. Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA 2009; 302: 1651–1657.
23. Bot M, Pouwer F, Assies J, Jansen EH, Diamant M, Snoek FJ et al. Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study. J Affect Disord 2010; 126: 282–286.
24. Olivo SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther 2008; 88: 156–175.
25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
26. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsycho-pharmacol 2003; 13: 267–271.
27. Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM et al. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry 2009; 70: 1636–1644.
28. Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006; 16: 601–611.
29. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573–583.
30. Kooshki A, Tofighiyan T. The effects of omega-3 fatty acids on depression in female students. [Persian]. Iran J Obstet Gynecol Infertil 2014; 17: 1–6.
31. Ginty AT, Conklin SM. Short-term supplementation of acute long-chain omega-3 polyunsaturated fatty acids may alter depression status and decrease sympto-mology among young adults with depression: a preliminary randomized and placebo controlled trial. Psychiatry Res 2015; 229: 485–489.
32. Park Y, Park YS, Kim SH, Oh DH, Park YC. Supplementation of n-3 polyunsaturated fatty acids for major depressive disorder: a randomized, double-blind, 12-week, placebo-controlled trial in Korea. Ann Nutr Metab 2015; 66: 141–148.
33. Silvers KM, Woolley CC, Hamilton FC, Watts PM, Watson RA. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Pros-taglandins Leukot Essent Fatty Acids 2005; 72: 211–218.
34. Gharekhani A, Khatami MR, Dashti-Khavidaki S, Razeghi E, Noorbala AA, Hashemi-Nazari SS et al. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial. Eur J Clin Pharmacol 2014; 70: 655–665.
35. Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA et al. A double-blind, randomized controlled clinical trial comparing eicosa-pentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry 2015; 76: 54–61.
36. Grenyer BF, Crowe T, Meyer B, Owen AJ, Grigonis-Deane EM, Caputi P et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1393–1396.
37. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477–479.
38. Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psycho-pharmacol 2012; 32: 61–64.
39. Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM et al. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry 2009; 70: 1636–1644.
40. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear LJ. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahex-aenoic acid in the treatment of major depression. Am J Psychiatry 2003; 160: 996–998.
41. Gonzalez A, Mata S, Sanchez P, Gonzalez D, Urbina M, Fazzino F et al. Omega-3 fatty acids as adjunctive of antidepressant therapy and its effects on brain-derived neurotrophic factor in serum, monocytes and lymphocytes. Arch Vene-zolanos Farmacol Ter 2011; 30: 72–78.
42. Fiedorowicz JG, Hale N, Spector AA, Coryell WH. Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram. Ann Clin Psychiatry 2010; 22: 157–163.
43. Schalkwijk S, Undurraga J, Tondo L, Baldessarini RJ. Declining efficacy in controlled trials of antidepressants: effects of placebo dropout. Int J Neuropsycho-pharmacol 2014; 17: 1343–1352.
44. Mocking RJ, Lok A, Assies J, Koeter MW, Visser I, Ruhe HG et al. Ala54Thr fatty acid-binding protein 2 (FABP2) polymorphism in recurrent depression: associations with fatty acid concentrations and waist circumference. PLoS One 2013; 8: e82980.
45. Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry 2016; 21: 71–79.
46. Mocking RJ, Assies J, Koeter MW, Ruhe HG, Lok A, Schene AH. Bimodal distribution of fatty acids in recurrent major depressive disorder. Biol Psychiatry 2012; 71: e3–e5.
47. Mocking RJT, Assies J, Bot M, Jansen EHJM, Schene AH, Pouwer F. Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: a randomized controlled trial. PLoS One 2012; 7: e49431.
48. Mocking RJ, Verburg HF, Westerink AM, Assies J, Vaz FM, Koeter MW et al. Fatty acid metabolism and its longitudinal relationship with the hypothalamic-pituitary-adrenal axis in major depression: associations with prospective antidepressant response. Psychoneuroendocrinology 2015; 59: 1–13.
49. Fisar Z. Interactions between tricyclic antidepressants and phospholipid bilayer membranes. Gen Physiol Biophys 2005; 24: 161–180.
50. Kodas E, Galineau L, Bodard S, Vancassel S, Guilloteau D, Besnard JC et al. Serotoninergic neurotransmission is affected by n-3 polyunsaturated fatty acids in the rat. J Neurochem 2004; 89: 695–702.
51. Kuan CY, Walker TH, Luo PG, Chen CF. Long-chain polyunsaturated fatty acids promote paclitaxel cytotoxicity via inhibition of the MDR1 gene in the human colon cancer Caco-2 cell line. J Am Coll Nutr 2011; 30: 265–273.
52. Bazinet RP, Laye S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 2014; 15: 771–785.
53. Russell FD, Burgin-Maunder CS. Distinguishing health benefits of eicosapentae-noic and docosahexaenoic acids. Mar Drugs 2012; 10: 2535–2559.
54. Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry 2010; 68: 140–147.
55. Serini S, Fasano E, Piccioni E, Cittadini AR, Calviello G. Dietary n-3 polyunsaturated fatty acids and the paradox of their health benefits and potential harmful effects. Chem Res Toxicol 2011; 24: 2093–2105.
56. Golomb BA, Erickson LC, Koperski S, Sack D, Enkin M, Howick J. What's in pla-cebos: who knows? Analysis of randomized, controlled trials. Ann Intern Med 2010; 153: 532–535.
57. Mocking RJT, Assies J, Lok A, Ruhe HG, Koeter MWJ, Visser I et al. Statistical methodological issues in handling of fatty acid data: percentage or concentration, imputation and indices. Lipids 2012; 47: 541–547.